The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback